EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Maternal and fetal outcomes in mice following exposure to dolutegravir alone or in combination with lamivudine or tenofovir disoproxil fumarate/emtricitabine

Haneesha Mohan iD, Jessica Nguyen, Audrey Yee, Evelyn Yukino Laurette, Jennifer Jao, Rebecca Zash, John G Sled, Nicholas D E Greene, Andrew J Copp, Lena Serghides iD

Research Connections · 05.10.2026 · 1 (4)

DOI: 10.1093/rescon/vmag173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research Connections, online erschienen am 26.09.2026. Verfasst von Haneesha Mohan und 9 weiteren Autor:innen. Beteiligte Einrichtung: University Health Network Research Institutes, University Health Network, Toronto, Ontario, M5G 1L7, Canada. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Dolutegravir (DTG)-based regimens are widely used in HIV treatment, including during pregnancy, but the contribution of the nucleoside reverse transcriptase inhibitor (NRTI) backbone on maternal and foetal outcomes remains unclear. We examined this in a large mouse fetotoxicity study.

Methods

Pregnant C57BL/6J mice were randomized to control (water), DTG-alone, DTG+ Lamivudine (3TC), or DTG+tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), and treated daily from GD0.5 to GD15.5 at clinically relevant doses. Maternal weight gain, litter size, foetal and placental weights, and foetal anomalies were assessed. Kruskal-Wallis and generalized ­linear models were used for statistical comparisons.

Results

Four hundred seventy two litters were evaluated (115 control, 106 DTG, 101 DTG + 3TC, 150 DTG + TDF/FTC). Foetal viability and resorptions were similar across groups. Maternal weight gain was significantly higher in the DTG and DTG + 3TC groups compared to control, but lower in DTG + TDF/FTC. Foetal and placental weights were significantly lower in DTG + TDF/FTC and DTG + 3TC groups versus controls, but not in DTG-alone. Nine neural tube defects occurred only in the DTG-exposed groups, most frequently in DTG + TDF/FTC. DTG was associated with higher rates of several foetal anomalies compared to controls, whether administered alone or in combination with NRTIs. Compared to DTG + TDF/FTC, cranial swelling and oedema rates were lower in DTG + 3TC, and tail and limb defects were higher in the DTG-alone group.

Conclusions

TDF inclusion was associated with absence of DTG-associated excess maternal weight gain. NRTI inclusion was associated with lower foetal and placental weights. DTG-associated maternal and foetal outcomes in mice vary by NRTI backbone, highlighting the importance of considering each regimen component, and need for ongoing safety evaluation in pregnancy.

Schlagwörter

Stichwörter der Autor:innen

DolutegravirNRTIfetotoxicityfoetal growth restrictionmaternal weight gainpregnancy

Autor:innen und Institutionen

  • University Health Network Research Institutes, University Health Network, Toronto, Ontario, M5G 1L7, Canada.
  • Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, United States.
  • Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, United States.
  • Department of Medicine, Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, 02215, United States.
  • Mouse Imaging Center, The Hospital for Sick Children, Toronto, Ontario, M5T 3H7, Canada.
  • Department of Medical Biophysics, University of Toronto, Toronto, Ontario, M5G 1L7, Canada.

ORCID-Profile: Haneesha Mohan, Lena Serghides

Förderung

  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institutes of Health
  • Tier 1 Canada Research Chair in Maternal-Child Health and HIV
  • Junior Investigator Award from the Ontario HIV Treatment Network

Zitieren

APA

Mohan, H., Nguyen, J., Yee, A., Laurette, E. Y., Jao, J., Zash, R., Sled, J. G., Greene, N. D. E., Copp, A. J., & Serghides, L. (2026). Maternal and fetal outcomes in mice following exposure to dolutegravir alone or in combination with lamivudine or tenofovir disoproxil fumarate/emtricitabine. Research Connections, 1(4). https://doi.org/10.1093/rescon/vmag173

Vancouver

Mohan H, Nguyen J, Yee A, Laurette EY, Jao J, Zash R, et al. Maternal and fetal outcomes in mice following exposure to dolutegravir alone or in combination with lamivudine or tenofovir disoproxil fumarate/emtricitabine. Research Connections. 2026;1(4). doi:10.1093/rescon/vmag173

BibTeX
@article{Mohan2026,
  author = {Mohan, Haneesha and Nguyen, Jessica and Yee, Audrey and Laurette, Evelyn Yukino and Jao, Jennifer and Zash, Rebecca and Sled, John G and Greene, Nicholas D E and Copp, Andrew J and Serghides, Lena},
  title = {Maternal and fetal outcomes in mice following exposure to dolutegravir alone or in combination with lamivudine or tenofovir disoproxil fumarate/emtricitabine},
  journal = {Research Connections},
  year = {2026},
  volume = {1},
  number = {4},
  doi = {10.1093/rescon/vmag173}
}
Kostenlos starten →